As hypothesized, a single i.t.-injection of Ad-CD40L-DC in combination with s.c. Ad-mAFP-DC-vaccination improved significantly the antitumoral immune response compared to Ad-LacZ-DC-vaccination and i.t.-injection of Ad-LacZ-DC (control treatment), reaching complete tumor remission in 62.5% of animals and long-term survival of more than 100 days (shown in Figure 2c,d). Here, CD40LG is linked to neoplasm.